Biotech Sector Turns Red-Hot on Alzheimer’s Treatment News In Phase 3 trials, a Biogen / Eisai Alzheimer’s drug slowed cognitive decline by 27%. 8 MIN READ 10.23.2022
Big Pharma and The Need for Speed Bayer is spending over $2B in the next 2.5 years to upgrade its manufacturing and supply chain. 4 MIN READ 10.16.2022
FDA Narrows Prescribing Instructions for Biogen’s Controversial Alzheimer’s Drug The FDA has faced an intense public backlash since its approval of Aduhelm (aducanumab) last month. 4 MIN READ 07.8.2021
FDA Comments Point to Biogen Getting Favorable Advisory Committee Vote on Alzheimer’s Drug Candidate FDA staff said Wednesday that Biogen has shown “exceptionally persuasive” evidence that its experimental Alzheimer’s disease drug is effective, ahead of Friday's Advisory Committee meeting. 3 MIN READ 11.4.2020
Epizyme Raises $75 Million in Follow-on Offering to Advance Epigenetic Cancer Therapies Lead candidate, tazemetostat, in Phase 2 for non-Hodgkin lymphoma, solid tumors and mesothelioma (Image: Epizyme). 4 MIN READ 10.3.2018
Eisai Commits Over $100 Million to New Dementia Discovery Center Drug discovery through integration of genetics and precision chemistry. 3 MIN READ 06.13.2018
